Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 07:10 ET
|
Werewolf Therapeutics, Inc.
- Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm...
Werewolf Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023 07:00 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023 07:00 ET
|
Werewolf Therapeutics, Inc.
- Progressing Phase 1/1b clinical trial for IL-2 INDUKINE WTX-124 in advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023...
Werewolf Therapeutics to Participate in May Investor Conferences
May 01, 2023 07:00 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research
April 19, 2023 10:00 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 23, 2023 07:00 ET
|
Werewolf Therapeutics, Inc.
– Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumors – – Dosed first patient in Phase...
UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023
March 16, 2023 07:30 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023
March 15, 2023 07:30 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
February 24, 2023 07:30 ET
|
Werewolf Therapeutics, Inc.
WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy Phase 1 Study of WTX-330 is intended to evaluate the safety, tolerability, and clinical activity of WTX-330 in...
Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 07, 2023 07:00 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Randi Isaacs, M.D., Chief Medical Officer of...